X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/gsk-launches-once-daily-single-inhaler-triple-therapy-for-copd-patients/articleshow/91095214.cms
https://www.pharmaceutical-technology.com/news/ema-gsk-trelegy-asthma-refusal/
https://www.expresspharma.in/drug-approvals/gsk-gets-us-fda-approval-for-trelegy-ellipta-to-treat-asthma-copd/
https://www.raps.org/news-and-articles/news-articles/2020/9/fda-approvals-roundup-detectnet-trelegy-ellipta-ni
https://www.fiercepharma.com/pharma/glaxosmithkline-eyes-novel-mortality-update-trelegy-s-label-but-analysts-say-fda-may-not-be
https://endpts.com/fda-requires-boxed-warning-for-singulair-and-its-generics/
https://www.gsk.com/en-gb/media/press-releases/gsk-filing-accepted-by-european-medicines-agency-for-trelegy-ellipta-use-in-adult-patients-with-asthma/
https://www.reuters.com/article/us-astrazeneca-fasenra/astrazeneca-respiratory-business-gets-boost-from-3-drug-inhaler-results-idUSKCN1VI0KB
https://www.fiercepharma.com/pharma/astrazeneca-s-copd-triplet-breztri-rival-to-gsk-s-trelegy-nabs-first-nod-from-japan
https://www.fiercepharma.com/pharma/teva-s-shaved-2-5b-costs-out-3b-goal-seeks-2020-growth
https://www.medtechdive.com/news/fda-draft-lays-out-submission-paths-for-combo-products/547807/
http://www.pharmatimes.com/news/eu_expands_label_of_gskinnovivas_copd_inhaler_1259755
https://www.prnewswire.com/news-releases/theravance-biopharma-highlights-expanded-copd-indication-for-trelegy-ellipta-in-europe-300748103.html
https://www.pharmaceutical-technology.com/news/vectura-hikma-ellipta-generic-versions/
https://www.fiercepharma.com/pharma/despite-tight-supply-gsk-s-shingrix-zooms-to-blockbuster-status
https://www.fiercepharma.com/manufacturing/glaxosmithkline-opens-expanded-api-production-for-copd-inhalers
https://endpts.com/hit-by-surprise-setback-astrazeneca-scrambles-to-explain-why-its-two-in-one-copd-inhaler-fails-to-beat-gsk-rival/
https://www.fiercepharma.com/pharma/gsk-trots-out-cost-cutting-drive-not-consumer-spin-q2-beats
https://www.gsk.com/en-gb/media/press-releases/gsk-submits-regulatory-application-in-japan-for-once-daily-single-inhaler-triple-therapy-ffumecvi-for-patients-with-copd/
http://www.pharmatimes.com/news/us_clears_paediatric_use_of_gsks_arnuity_ellipta_1236328
http://investor.inva.com/news-releases/news-release-details/once-daily-trelegy-ellipta-gains-expanded-indication-us
http://www.pharmatimes.com/news/eu_expands_scope_of_gskinnovivas_asthma_inhaler_1226718
https://www.pharmacompass.com/pdf/news/glaxosmithklines-elebrato-ellipta-lfluticasone-furoate-umeclidinium-vilanterol-receives-approval-in-europe-1517032320.pdf
http://www.pharmatimes.com/news/gsk,_innovivas_trelegy_ellipta_cleared_for_copd_1211588
http://www.pharmatimes.com/news/chmp_backs_13_treatments_for_eu_approval_1205544
http://www.pmlive.com/pharma_news/gsk_closes_in_on_eu_approval_for_triple_copd_therapy_1205641
http://www.reuters.com/article/us-gsk-copd-approval/gsks-three-in-one-inhaler-gets-positive-opinion-from-eu-agency-idUSKCN1BQ0M0
http://www.pharmatimes.com/news/gsks_inhaler_improves_asthma_control_in_real_world_study_1192433
http://www.fiercepharma.com/marketing/teva-s-airduo-steps-up-to-challenge-advair-but-newcomer-s-fate-depends-price
http://www.pharmatimes.com/news/gsk_files_triple_combo_for_copd_in_europe_1180010
http://www.fiercepharma.com/pharma/specialty-drugs-big-price-tags-top-market-performance-report-finds
http://www.pmlive.com/pharma_news/gsks_bexsero_vaccine_growing_fast,_despite_tight_supply_1174879
http://www.prnewswire.com/news-releases/fda-approves-flonase-sensimist-allergy-relief-300308201.html
http://www.pmlive.com/pharma_news/gsks_triple_copd_therapy_tops_symbicort_in_phase_iii_trial_1044758
http://www.reuters.com/article/us-gsk-lung-study-idUSKCN0YF17S
http://www.fiercepharma.com/marketing/gsk-finally-has-breo-where-it-wants-it-just-time-for-advair-copies
http://www.fiercepharmamarketing.com/story/pharmas-dtc-ad-spending-soars-past-5-billion-2015/2016-03-07
www.seekingalpha.com/article/3839766-will-glaxosmithklines-triple-therapy-combination-perform-market
http://www.fiercepharmamarketing.com/story/pharmas-december-tv-spending-sags-pfizer-and-bms-eliquis-rises-top/2016-01-20
http://www.fiercepharma.com/story/advera-health-novartis-gsk-asthma-meds-linked-more-side-effects-merck-drugs/2015-11-18
http://www.marketwatch.com/story/regulatory-update-gsk-and-theravance-announce-intention-to-file-relvarr-elliptar-for-copd-in-japan-2015-09-24
http://www.bloomberg.com/news/articles/2015-05-05/prescription-for-glaxo-a-new-boss-
http://www.gsk.com/en-gb/media/press-releases/2015/fda-approves-breo-ellipta-for-the-treatment-of-adults-with-asthma-in-the-us/
http://images.info.science.thomsonreuters.biz/Web/ThomsonReutersScience/%7B7e677448-1313-40ae-9978-6be1a8532a08%7D_A4_MarketInsight_Report_0213_012__edits_2.pdf
http://www.fiercepharma.com/story/gsks-breo-asthma-fda-panel-says-yes-only-adults/2015-03-19
Market Place
Share 
